Oura is going public at a $15.6 billion valuation and the loudest number in the filing is not revenue. It is the $1.26 billion that Forerunner Ventures plans to pocket by selling its entire stake. That is the structure of the modern wearables IPO: the product is the pitch, the exit is the point.

When the Ring Becomes the Return

Oura is genuinely interesting hardware. A sleep-tracking ring that has accumulated real clinical partnerships and a devoted user base is not nothing. But the IPO document reads less like a growth story and more like a liquidity event dressed in wellness language. A 2026 paper in arXiv by Marcin Marciniak argues that AI and adjacent tech are increasingly discussed as transformations rather than as businesses, which lets the valuation float free of the underlying economics. Oura is a clean case study. The transformation narrative — continuous health monitoring, preventive medicine, the quantified self — does real work in the prospectus, while the actual question of whether the ring prints money gets softer treatment.

The Forerunner Problem and What It Tells Us About Consumer Hardware

Forerunner selling everything is not a scandal. Funds have mandates and timelines. But it does compress the signal. When the VC most associated with a product's consumer credibility is the first one out the door, the market is left holding a thesis, not a stake. Reuters notes that the IPO is a test of fall listings demand broadly, which means Oura is also a weather balloon for whether the public markets still have appetite for consumer health hardware. That appetite is real, but it has been educated by a decade of fitness trackers that dominated CES and then disappeared into the junk drawer. The ring is prettier than a Fitbit. The exit math is identical.